It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Christopher G. Goetz, MD

Specialty:
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Professor
Medical or Graduate Education: Rush Medical College
Residency: Michael Reese Hospital and Medical Center - Neurology
  Rush University Medical Center - Neurology
Clinical Expertise:
  • Corticobasal degeneration
  • Dystonia
  • Hemifacial spasm
  • Huntington's disease
  • Movement disorders
  • Movement disorders, fragile X-associated
  • Multiple system atrophy
  • Myoclonus
  • Parkinsonism
  • Parkinson's disease
  • Progressive supranuclear palsy (PSP)
  • Restless legs syndrome (RLS)
  • Stiff-person syndrome
  • Tics
  • Tourette syndrome
  • Tremor
  • Wilson disease
  • Writer's cramp
Research Interests:
  • Parkinson disease
  • Tourette's syndrome
  • Huntington disease
  • Dystonia
  • Neuropsychiatric features and genetics of Parkinson disease
  • Clinical trials in Parkinson disease
  • Pharmacological studies of movement disorders
  • Cognition in Parkinson disease
Languages Spoken:
  • French
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Official Japanese Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale: validation against the original English version.
    Kashihara K, Kondo T, Mizuno Y, Kikuchi S, Kuno S, Hasegawa K, Hattori N, Mochizuki H, Mori H, Murata M, Nomoto M, Takahashi R, Takeda A, Tsuboi Y, Ugawa Y, Yamanmoto M, Yokochi F, Yoshii F, Stebbins GT, Tilley BC, Luo S, Wang L, LaPelle NR, Goetz CG,
    Mov Disord Clin Pract (Hoboken)
    2014 Sep 1
    1(3):200-212.
    ENG
  2. The past, present, and future of telemedicine for Parkinson's disease.
    Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Ray Dorsey E, Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson JR,
    Mov. Disord.
    2014 May 17
  3. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing.
    Barton BR, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG
    Mov. Disord.
    2014 May 13
  4. A practical approach to remote longitudinal follow-up of Parkinson's disease: The FOUND study.
    Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, Dieuliis D, Fahn S, Elliott RA, Shoulson I
    Mov. Disord.
    2014 May
    29(6):743-9.
  5. Using Cognitive Pretesting in Scale Development for Parkinson's Disease: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Example.
    Tilley BC, La Pelle NR, Goetz CG, Stebbins GT
    J Parkinsons Dis
    2014 Mar 10
  6. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.
    Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG
    Brain
    2014 Mar
    137(Pt 3):849-59.
  7. Maynard M Cohen, MD, PhD (1920-2014).
    Goetz CG, Bergen DC
    Neurology
    2014 Jun 3
    82(22):1944-5.
  8. Are patients with Parkinson's disease blind to blindsight?
    Diederich NJ, Stebbins G, Schiltz C, Goetz CG
    Brain
    2014 Jun
    137(Pt 6):1838-49.
  9. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
    , Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K
    JAMA Neurol
    2014 Feb
    71(2):141-50.
  10. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS.
    Goldman JG, Stebbins GT, Leung V, Tilley BC, Goetz CG
    Parkinsonism Relat. Disord.
    2014 Aug 13
    :.
    ENG
  11. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.
    Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G
    Mov. Disord.
    2014 Apr
    29(4):454-62.
    eng
  12. Task force report: Scales for screening and evaluating tremor: Critique and recommendations.
    Elble R, Bain P, João Forjaz M, Haubenberger D, Testa C, Goetz CG, Leentjens AF, Martinez-Martin P, Pavy-Le Traon A, Post B, Sampaio C, Stebbins GT, Weintraub D, Schrag A
    Mov. Disord.
    2013 Sep 3
    :.
    ENG
  13. Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments.
    Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I,
    Mov. Disord.
    2013 Oct 9
    :.
    ENG
  14. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.
    Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT
    Mov. Disord.
    2013 Oct 9
  15. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor.
    Prodoehl J, Li H, Planetta PJ, Goetz CG, Shannon KM, Tangonan R, Comella CL, Simuni T, Zhou XJ, Leurgans S, Corcos DM, Vaillancourt DE.
    Mov Disord. 2013
    2013 May 14. doi: 10.1002/mds.25491. [Epub ahead of print]
  16. The parkinson's disease multidisciplinary package.
    Goetz CG.
    Mov Disord. 2013
    2013 Mar 11. doi: 10.1002/mds.25414. [Epub ahead of print] No abstract available.
  17. Which dyskinesia scale best detects treatment response?
    Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S.
    Mov Disord. 2013
    2013 Mar
    28(3):341-6. doi: 10.1002/mds.25321. Epub 2013 Feb 6.
  18. Assessing bradykinesia in parkinsonian disorders.
    Pal G, Goetz CG.
    Front Neurol. 2013
    2013 Jun 3
    4:54. doi: 10.3389/fneur.2013.00054. Print 2013.
  19. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease.
    Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT.
    Parkinsonism Relat Disord. 2013
    2013 Jun 2. doi:pii: S1353-8020(13)00193-4. 10.1016/j.parkreldis.2013.05.006. [Epub ahead of print]
  20. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease.
    Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG, Martinez-Martin P.
    Parkinsonism Relat Disord. 2013
    2013 Jun 19. doi:pii: S1353-8020(13)00204-6. 10.1016/j.parkreldis.2013.05.017. [Epub ahead of print]
  21. Dystonia rating scales: Critique and recommendations.
    Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A
    Mov. Disord.
    2013 Jun 15
    28(7):874-83.
  22. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.
    Dodel R, Jönsson B, Reese JP, Winter Y, Martinez-Martin P, Holloway R, Sampaio C, Ružicka E, Hawthorne G, Oertel W, Poewe W, Stebbins G, Rascol O, Goetz CG, Schrag A
    Mov. Disord.
    2013 Jul 16
  23. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging.
    Goetz CG, Vaughan CL, Goldman JG, Stebbins GT.
    Mov Disord. 2013
    2013 Jul 10. doi: 10.1002/mds.25554. [Epub ahead of print]
  24. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
    Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG.
    J Neurol. 2013
    2013 Jan
    260(1):228-36. doi: 10.1007/s00415-012-6624-1. Epub 2012 Aug 5.
  25. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale.
    Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC.
    Mov Disord. 2013
    2013 Feb 13. doi: 10.1002/mds.25383. [Epub ahead of print]
  26. Babinski's contributions to cerebellar symptomatology: building the basis of the neurological examination.
    Pedroso JL, Barsottini OG, Goetz CG
    Arq Neuropsiquiatr
    2013 Dec
    71(12):973-5.
  27. Treating melancholia at home: Theoretical wisdom and grim reality in the career of E.C. Seguin.
    Goetz CG, Harter DH.
    Neurology. 2013
    2013 Apr 30
    80(18):1710-4. doi: 10.1212/WNL.0b013e3182904f55.
  28. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.
    Neely KA, Planetta PJ, Prodoehl J, Corcos DM, Comella CL, Goetz CG, Shannon KL, Vaillancourt DE.
    PLoS One. 2013
    2013
    8(3):e58403. doi: 10.1371/journal.pone.0058403. Epub 2013 Mar 11.
  29. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores.
    Goetz CG, Stebbins GT, Tilley BC.
    Mov Disord. 2012
    2012 Sep 1
    27(10):1239-42. doi: 10.1002/mds.25122. Epub 2012 Aug 6.
  30. Tai chi for patients with Parkinson's disease.
    Corcos DM, Comella CL, Goetz CG.
    N Engl J Med. 2012
    2012 May 3
    366(18):1737-8; author reply 1738. doi: 10.1056/NEJMc1202921#SA2. No abstract available.
  31. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia.
    Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L.
    Mov Disord. 2012
    2012 May
    27(6):727-34. doi: 10.1002/mds.24938. Epub 2012 Mar 12.
  32. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale.
    Seidel SE, Tilley BC, Huang P, Palesch YY, Bergmann KJ, Goetz CG, Swearingen CJ.
    Parkinsonism Relat Disord. 2012
    2012 Mar
    18(3):230-3. doi: 10.1016/j.parkreldis.2011.10.006. Epub 2011 Oct 21.
  33. Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Antonini A, Abbruzzese G, Ferini-Strambi L, Tilley B, Huang J, Stebbins GT, Goetz CG, Barone P; MDS-UPDRS Italian Validation Study Group, Bandettini di Poggio M, Fabbrini G, Di Stasio F, Tinazzi M, Bovi T, Ramat S, Meoni S, Pezzoli G, Canesi M, Martinelli P, Maria Scaglione CL, Rossi A, Tambasco N, et al.
    Neurol Sci. 2012
    2012 Jun 8. [Epub ahead of print]
  34. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations.
    Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ.
    Lancet Neurol. 2012
    2012 Jul
    11(7):643-50. doi: 10.1016/S1474-4422(12)70064-9.
  35. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease.
    Gallagher DA, Goetz CG, Stebbins G, Lees AJ, Schrag A.
    Mov Disord. 2012
    2012 Jan
    27(1):79-83. doi: 10.1002/mds.23939. Epub 2011 Sep 13.
  36. Dopamine dysregulation syndrome item from the MDS-UPDRS.
    Goetz CG, Tilley BC, Stebbins GT.
    Mov Disord. 2012
    2012 Jan
    27(1):166. doi: 10.1002/mds.23910. Epub 2011 Oct 24. No abstract available.
  37. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia.
    Barton B, Grabli D, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG.
    Mov Disord. 2012
    2012 Feb
    27(2):248-53. doi: 10.1002/mds.24059. Epub 2011 Dec 9.
  38. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.
    Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG.
    Mov Disord. 2012
    2012 Aug
    27(9):1129-36. doi: 10.1002/mds.25062. Epub 2012 Jul 6.
  39. Vibration Therapy for Parkinson's Disease: Charcot's Studies Revisited.
    Kapur SS, Stebbins GT, Goetz CG
    J Parkinsons Dis
    2012
    2(1):23-7.
  40. The history of Parkinson's disease: early clinical descriptions and neurological therapies.
    Goetz CG.
    Cold Spring Harb Perspect Med. 2011
    2011 Sep
    1(1):a008862. doi: 10.1101/cshperspect.a008862.
  41. An update expert opinion on management and research strategies in Parkinson's disease psychosis.
    Goldman JG, Vaughan CL, Goetz CG.
    Expert Opin Pharmacother. 2011
    2011 Sep
    12(13):2009-24. doi: 10.1517/14656566.2011.587122. Epub 2011 Jun 2. Review.
  42. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension.
    Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftman SR, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Stebbins GT, Rascol O.
    Mov Disord. 2011
    2011 Sep
    26(11):1985-92. doi: 10.1002/mds.23742. Epub 2011 May 5. Review.
  43. Wearing-off scales in Parkinson's disease: critique and recommendations.
    Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG.
    Mov Disord. 2011
    2011 Oct
    26(12):2169-75. doi: 10.1002/mds.23875. Epub 2011 Jul 20. Review.
  44. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years.
    Goetz CG, Stebbins GT, Ouyang B.
    Mov Disord. 2011
    2011 Oct
    26(12):2196-200. doi: 10.1002/mds.23835. Epub 2011 Jul 13.
  45. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
    Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C.
    Mov Disord. 2011
    2011 Oct
    26 Suppl 3:S42-80. doi: 10.1002/mds.23884. Review.
  46. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.
    Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C.
    Mov Disord. 2011
    2011 Oct
    26 Suppl 3:S2-41. doi: 10.1002/mds.23829. Review.
  47. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations.
    Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A.
    Mov Disord. 2011
    2011 Nov
    26(13):2371-80. doi: 10.1002/mds.23834. Epub 2011 Jul 6. Review.
  48. Priorities in Parkinson's disease research.
    Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E.
    Nat Rev Drug Discov. 2011
    2011 May
    10(5):377-93. doi: 10.1038/nrd3430. Review.
  49. The movement disorder society and movement disorders: a modern history.
    Goetz CG, McGhiey A.
    Mov Disord. 2011
    2011 May
    26(6):939-46. doi: 10.1002/mds.23689. Review.
  50. Temporal stability of the Unified Dyskinesia Rating Scale.
    Goetz CG, Stebbins GT, Theeuwes A, Stocchi F, Ferreira JJ, van de Witte S, Bronzova J.
    Mov Disord. 2011
    2011 Dec
    26(14):2556-9. doi: 10.1002/mds.23931. Epub 2011 Sep 13.
  51. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations.
    Goldman JG, Marr D, Zhou L, Ouyang B, Leurgans SE, Berry-Kravis E, Goetz CG.
    Mov Disord. 2011
    2011 Aug 1
    26(9):1781-2. doi: 10.1002/mds.23655. Epub 2011 Apr 19. No abstract available.
  52. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
    Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C.
    Mov Disord. 2010
    2010 Sep 15
    25(12):1801-8. doi: 10.1002/mds.23006.
  53. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study.
    Goetz CG, Ouyang B, Negron A, Stebbins GT.
    Neurology. 2010
    2010 Nov 16
    75(20):1773-9. doi: 10.1212/WNL.0b013e3181fd6158. Epub 2010 Oct 20.
  54. Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor.
    Goetz CG.
    Neurology. 2010
    2010 May 25
    74(21):1739-42. doi: 10.1212/WNL.0b013e3181e0439e.
  55. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease.
    Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A.
    Mov Disord. 2010
    2010 May 15
    25(7):805-22. doi: 10.1002/mds.22989. Review.
  56. Missing pieces in the Parkinson's disease puzzle.
    Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G.
    Nat Med. 2010
    2010 Jun
    16(6):653-61. doi: 10.1038/nm.2165. Epub 2010 May 23. Review.
  57. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.
    Colosimo C, Martínez-Martín P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG.
    Mov Disord. 2010
    2010 Jul 15
    25(9):1131-42. doi: 10.1002/mds.23072. Review.
  58. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS).
    Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM.
    Mov Disord. 2010
    2010 Jul 15
    25(9):1190-4. doi: 10.1002/mds.23096.
  59. Fibroblast phenotype in male carriers of FMR1 premutation alleles.
    Garcia-Arocena D, Yang JE, Brouwer JR, Tassone F, Iwahashi C, Berry-Kravis EM, Goetz CG, Sumis AM, Zhou L, Nguyen DV, Campos L, Howell E, Ludwig A, Greco C, Willemsen R, Hagerman RJ, Hagerman PJ.
    Hum Mol Genet. 2010
    2010 Jan 15
    19(2):299-312. doi: 10.1093/hmg/ddp497. Epub 2009 Oct 28.
  60. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations.
    Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG.
    Mov Disord. 2010
    2010 Dec 15
    25(16):2704-16. doi: 10.1002/mds.23190. Review.
  61. A 12-year population-based study of psychosis in Parkinson disease.
    Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G.
    Arch Neurol. 2010
    2010 Aug
    67(8):996-1001. doi: 10.1001/archneurol.2010.166.
  62. Association between antipsychotics and body mass index when treating patients with tics.
    Kompoliti K, Stebbins GT, Goetz CG, Fan W.
    J Child Adolesc Psychopharmacol. 2010
    2010 Aug
    20(4):277-81. doi: 10.1089/cap.2009.0091.
  63. Chapter 15: Jean-Martin Charcot and the anatomo-clinical method of neurology.
    Goetz CG.
    Handb Clin Neurol. 2010
    2010
    95:203-12. doi: 10.1016/S0072-9752(08)02115-5.
  64. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease.
    Goetz CG.
    Mov Disord. 2010
    2010
    25 Suppl 1:S104-9. doi: 10.1002/mds.22636.
  65. Using global statistical tests in long-term Parkinson's disease clinical trials.
    Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kieburtz K; Parkinson Study Group.
    Mov Disord. 2009
    2009 Sep 15
    24(12):1732-9. doi: 10.1002/mds.22645.
  66. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
    Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators.
    Mov Disord. 2009
    2009 Oct 30
    24(14):2081-90. doi: 10.1002/mds.22690.
  67. Charcot and Pasteur: intersecting orbits in fin de siècle French medicine.
    Goetz CG, Harter DH.
    J Hist Neurosci. 2009
    2009 Oct
    18(4):378-86. doi: 10.1080/09647040802536967.
  68. Determinants of quality of life in children with Gilles de la Tourette syndrome.
    Bernard BA, Stebbins GT, Siegel S, Schultz TM, Hays C, Morrissey MJ, Leurgans S, Goetz CG.
    Mov Disord. 2009
    2009 May 15
    24(7):1070-3. doi: 10.1002/mds.22487.
  69. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device.
    Goetz CG, Stebbins GT, Wolff D, DeLeeuw W, Bronte-Stewart H, Elble R, Hallett M, Nutt J, Ramig L, Sanger T, Wu AD, Kraus PH, Blasucci LM, Shamim EA, Sethi KD, Spielman J, Kubota K, Grove AS, Dishman E, Taylor CB.
    Mov Disord. 2009
    2009 Mar 15
    24(4):551-6. doi: 10.1002/mds.22379.
  70. Hallucinations in Parkinson disease.
    Diederich NJ, Fénelon G, Stebbins G, Goetz CG.
    Nat Rev Neurol. 2009
    2009 Jun
    5(6):331-42. doi: 10.1038/nrneurol.2009.62. Review.
  71. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol. 2009
    2009 Jul-Aug
    32(4):189-92. doi: 10.1097/WNF.0b013e3181a27fae.
  72. Teaching program for the Unified Dyskinesia Rating Scale.
    Goetz CG, Nutt JG, Stebbins GT, Chmura TA.
    Mov Disord. 2009
    2009 Jul 15
    24(9):1296-8. doi: 10.1002/mds.22563.
  73. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA.
    Mov Disord. 2009
    2009 Feb 15
    24(3):336-43. doi: 10.1002/mds.22208.
  74. Scales to evaluate psychosis in Parkinson's disease.
    Goetz CG.
    Parkinsonism Relat Disord. 2009
    2009 Dec
    15 Suppl 3:S38-41. doi: 10.1016/S1353-8020(09)70777-1.
  75. Jean-Martin Charcot and his vibratory chair for Parkinson disease.
    Goetz CG.
    Neurology. 2009
    2009 Aug 11
    73(6):475-8. doi: 10.1212/WNL.0b013e3181b1640b.
  76. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease.
    Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti K, Yang C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG.
    Mov Disord. 2009
    2009 Apr 15
    24(5):635-46. doi: 10.1002/mds.22260. Review.
  77. Movement disorders caused by medical disease.
    Barton B, Zauber SE, Goetz CG.
    Semin Neurol. 2009
    2009 Apr
    29(2):97-110. doi: 10.1055/s-0029-1213731. Epub 2009 Apr 15. Review.
  78. Anxiety rating scales in Parkinson's disease: critique and recommendations.
    Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG.
    Mov Disord. 2008
    2008 Oct 30
    23(14):2015-25. doi: 10.1002/mds.22233.
  79. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations.
    Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG.
    Mov Disord. 2008
    2008 Oct 30
    23(14):2004-14. doi: 10.1002/mds.22229.
  80. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
    Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, et al.
    Mov Disord. 2008
    2008 Nov 15
    23(15):2129-70. doi: 10.1002/mds.22340.
  81. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies.
    Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT.
    Mov Disord. 2008
    2008 Nov 15
    23(15):2248-50. doi: 10.1002/mds.22322.
  82. Scales to assess psychosis in Parkinson's disease: Critique and recommendations.
    Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG.
    Mov Disord. 2008
    2008 Mar 15
    23(4):484-500. doi: 10.1002/mds.21875.
  83. Concerning about the accuracy of data reported.
    Goetz CG.
    Mov Disord. 2008
    2008 Mar 15
    23(4):473; author reply 473. doi: 10.1002/mds.22042. No abstract available.
  84. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
    Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J.
    Arch Neurol. 2008
    2008 Jun
    65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14.
  85. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies.
    Diederich NJ, Leurgans S, Fan W, Chmura TA, Goetz CG.
    Int J Geriatr Psychiatry. 2008
    2008 Jun
    23(6):598-603.
  86. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments.
    Goetz CG, Leurgans S, Hinson VK, Blasucci LM, Zimmerman J, Fan W, Nguyen T, Hsu A.
    Mov Disord. 2008
    2008 Jul 30
    23(10):1479-82. doi: 10.1002/mds.22127.
  87. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.
    Goetz CG, Nutt JG, Stebbins GT.
    Mov Disord. 2008
    2008 Dec 15
    23(16):2398-403. doi: 10.1002/mds.22341.
  88. Comparison of tic characteristics between children and adults.
    Cubo E, Chmura T, Goetz CG.
    Mov Disord. 2008
    2008 Dec 15
    23(16):2407-11. doi: 10.1002/mds.22117.
  89. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.
    Goetz CG, Emre M, Dubois B.
    Ann Neurol. 2008
    2008 Dec
    64 Suppl 2:S81-92. doi: 10.1002/ana.21455.
  90. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies.
    Diederich NJ, Goetz CG.
    Neurology. 2008
    2008 Aug 26
    71(9):677-84. doi: 10.1212/01.wnl.0000324635.49971.3d. Review.
  91. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening.
    Goetz CG, Fan W, Leurgans S.
    Mov Disord. 2008
    2008 Aug 15
    23(11):1541-5. doi: 10.1002/mds.22132.
  92. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.
    Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK; Parkinson Study Group, Leurgans S.
    Mov Disord. 2008
    2008 Apr 15
    23(5):690-9. doi: 10.1002/mds.21894.
  93. Placebo influences on dyskinesia in Parkinson's disease.
    Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, Russ H.
    Mov Disord. 2008
    2008 Apr 15
    23(5):700-7. doi: 10.1002/mds.21897.
  94. fMRI activation changes during successful episodic memory encoding and recognition in amnestic mild cognitive impairment relative to cognitively healthy older adults.
    Trivedi MA, Murphy CM, Goetz C, Shah RC, Gabrieli JD, Whitfield-Gabrieli S, Turner DA, Stebbins GT.
    Dement Geriatr Cogn Disord. 2008
    2008
    26(2):123-37. doi: 10.1159/000148190. Epub 2008 Jul 28.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript